These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 29113396)

  • 1. Epidermal growth factor receptor is associated with the onset of skeletal related events in non-small cell lung cancer.
    Huang SM; Yang JJ; Chen HJ; Wu SP; Bai XY; Zhou Q; Tu HY; Wu YL
    Oncotarget; 2017 Oct; 8(46):81369-81376. PubMed ID: 29113396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases.
    Laganà M; Gurizzan C; Roca E; Cortinovis D; Signorelli D; Pagani F; Bettini A; Bonomi L; Rinaldi S; Berardi R; Filetti M; Giusti R; Pilotto S; Milella M; Intagliata S; Baggi A; Cortellini A; Soto Parra H; Brighenti M; Petrelli F; Bennati C; Bidoli P; Garassino MC; Berruti A
    Front Oncol; 2020; 10():588862. PubMed ID: 33282740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skeletal-related events in advanced lung adenocarcinoma patients evaluated EGFR mutations.
    Nagata M; Kudoh S; Mitsuoka S; Suzumura T; Umekawa K; Tanaka H; Matsuura K; Kimura T; Yoshimura N; Hirata K
    Osaka City Med J; 2013 Jun; 59(1):45-52. PubMed ID: 23909080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases.
    Sun JM; Ahn JS; Lee S; Kim JA; Lee J; Park YH; Park HC; Ahn MJ; Ahn YC; Park K
    Lung Cancer; 2011 Jan; 71(1):89-93. PubMed ID: 20598769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overall Survival Improvement in Patients with Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer and Bone Metastasis Treated with Denosumab.
    Ko HW; Chiu CT; Wang CL; Yang TY; Liu CY; Yu CT; Tseng LC; Kuo CS; Wang CC; Yang MH; Yang CT
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of skeletal-related events in patients with non-small cell lung cancer.
    Aiba H; Kimura T; Yamagami T; Watanabe N; Sakurai H; Kimura H; Shimozaki S; Yamada S; Otsuka T
    Support Care Cancer; 2016 Aug; 24(8):3361-7. PubMed ID: 26980332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for skeletal-related events (SREs) and factors affecting SRE-free survival for nonsmall cell lung cancer patients with bone metastases.
    Ulas A; Bilici A; Durnali A; Tokluoglu S; Akinci S; Silay K; Oksuzoglu B; Alkis N
    Tumour Biol; 2016 Jan; 37(1):1131-40. PubMed ID: 26276360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective study on the incidence of bone metastasis (BM) and skeletal-related events (SREs) in patients (pts) with stage IIIB and IV lung cancer-CSP-HOR 13.
    Katakami N; Kunikane H; Takeda K; Takayama K; Sawa T; Saito H; Harada M; Yokota S; Ando K; Saito Y; Yokota I; Ohashi Y; Eguchi K
    J Thorac Oncol; 2014 Feb; 9(2):231-8. PubMed ID: 24419421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
    Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
    Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis.
    Zhang Q; Zhang X; Yan H; Jiang B; Xu C; Yang J; Chen Z; Su J; Wu YL; Zhou Q
    Thorac Cancer; 2016 Nov; 7(6):648-654. PubMed ID: 27755835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Factors in Lung Adenocarcinoma with Bone Metastasis Treated with EGFR-TKIs.
    Chiu TH; Lin CY; Hsieh MH; Lin SM; Fang YF
    Medicina (Kaunas); 2021 Sep; 57(9):. PubMed ID: 34577890
    [No Abstract]   [Full Text] [Related]  

  • 12. Skeletal related events in patients with bone metastasis arising from non-small cell lung cancer.
    da Silva GT; Bergmann A; Thuler LCS
    Support Care Cancer; 2016 Feb; 24(2):731-736. PubMed ID: 26143039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors.
    Chen YM; Lai CH; Rau KM; Huang CH; Chang HC; Chao TY; Tseng CC; Fang WF; Chung YH; Wang YH; Su MC; Huang KT; Liu SF; Chen HC; Chang YC; Chang YP; Wang CC; Lin MC
    BMC Cancer; 2016 Nov; 16(1):868. PubMed ID: 27821111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
    Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
    Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis.
    Byeon S; Ham JS; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Med Oncol; 2016 Aug; 33(8):97. PubMed ID: 27447711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Survival analysis of different kinds of tyrosine kinase inhibitors in the treatment of patients with epidermal growth factor receptor mutated non-small cell lung cancer and leptomeningeal metastasis].
    Xu HY; Chen HQ; Kong JX; Zhang Y; Liu S; Yang GJ; Wang Y
    Zhonghua Yi Xue Za Zhi; 2022 Feb; 102(6):399-405. PubMed ID: 35144338
    [No Abstract]   [Full Text] [Related]  

  • 17. The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer.
    Zhao M; Zhang Y; Cai W; Li J; Zhou F; Cheng N; Ren R; Zhao C; Li X; Ren S; Zhou C; Hirsch FR
    Cancer; 2014 Aug; 120(15):2299-307. PubMed ID: 24737648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors.
    Lee JY; Ku BM; Lim SH; Lee MY; Kim H; Kim M; Kim S; Jung HA; Sun JM; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2015 Jun; 10(6):903-9. PubMed ID: 26001141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The peripheral blood neutrophil-to-lymphocyte ratio is a prognostic predictor for survival of EGFR-mutant nonsmall cell lung cancer patients treated with EGFR-TKIs.
    Zhang Y; Feng YC; Zhu HG; Xiong TC; Hou YS; Song J; Jiang W; Zhu CJ
    Medicine (Baltimore); 2018 Jul; 97(30):e11648. PubMed ID: 30045314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases.
    Yu X; Sheng J; Pan G; Fan Y
    Int J Cancer; 2021 Sep; 149(5):1121-1128. PubMed ID: 33970485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.